Do analysts prefer DWTX or GDTC?

Dogwood Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 640.74%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Dogwood Therapeutics is more favorable than CytoMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, DWTX or GDTC?

CytoMed Therapeutics has higher revenue and earnings than Dogwood Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A CytoMed Therapeutics $250K 55.79 -$3.10M N/A N/A

Is DWTX or GDTC more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -108.57% -30.28% CytoMed Therapeutics N/A N/A N/A

Does the media prefer DWTX or GDTC?

In the previous week, Dogwood Therapeutics and Dogwood Therapeutics both had 3 articles in the media. CytoMed Therapeutics' average media sentiment score of 1.32 beat Dogwood Therapeutics' score of 0.96 indicating that CytoMed Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytoMed Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend GDTC or XLO?

Xilio Therapeutics has a consensus price target of $28.00, suggesting a potential upside of 233.73%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Xilio Therapeutics is more favorable than CytoMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better valuation & earnings, GDTC or XLO?

CytoMed Therapeutics has higher earnings, but lower revenue than Xilio Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CytoMed Therapeutics $250K 55.79 -$3.10M N/A N/A Xilio Therapeutics $53.48M 1.03 -$35.04M -$3.55 N/A

Does the media prefer GDTC or XLO?

In the previous week, CytoMed Therapeutics had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for CytoMed Therapeutics and 2 mentions for Xilio Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.32 beat Xilio Therapeutics' score of 1.31 indicating that CytoMed Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytoMed Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xilio Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MGX or GDTC?

Metagenomi presently has a consensus target price of $9.00, suggesting a potential upside of 634.69%. Given Metagenomi's stronger consensus rating and higher probable upside, equities analysts clearly believe Metagenomi is more favorable than CytoMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, MGX or GDTC?

CytoMed Therapeutics has lower revenue, but higher earnings than Metagenomi. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Metagenomi $25.21M 1.83 -$87.87M -$2.30 N/A CytoMed Therapeutics $250K 55.79 -$3.10M N/A N/A

Does the media refer more to MGX or GDTC?

In the previous week, Metagenomi had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 4 mentions for Metagenomi and 3 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.32 beat Metagenomi's score of 0.29 indicating that CytoMed Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CytoMed Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ESLA or GDTC?

CytoMed Therapeutics has higher revenue and earnings than Estrella Immunopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A CytoMed Therapeutics $250K 55.79 -$3.10M N/A N/A

Is ESLA or GDTC more profitable?

Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -397.36% CytoMed Therapeutics N/A N/A N/A

Does the media refer more to ESLA or GDTC?

In the previous week, CytoMed Therapeutics had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 3 mentions for CytoMed Therapeutics and 2 mentions for Estrella Immunopharma. CytoMed Therapeutics' average media sentiment score of 1.32 beat Estrella Immunopharma's score of 0.94 indicating that CytoMed Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytoMed Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, MREO or GDTC?

CytoMed Therapeutics has lower revenue, but higher earnings than Mereo BioPharma Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mereo BioPharma Group $500K 99.92 -$41.88M -$0.05 N/A CytoMed Therapeutics $250K 55.79 -$3.10M N/A N/A

Is MREO or GDTC more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group N/A -81.28% -70.45% CytoMed Therapeutics N/A N/A N/A

Does the media favor MREO or GDTC?

In the previous week, Mereo BioPharma Group and Mereo BioPharma Group both had 3 articles in the media. CytoMed Therapeutics' average media sentiment score of 1.32 beat Mereo BioPharma Group's score of 1.30 indicating that CytoMed Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mereo BioPharma Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytoMed Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CytoMed Therapeutics (GDTC) Competitors

$1.18 +0.04 (+3.42%)

As of 10:03 AM Eastern

Compare

GDTC vs. DWTX, XLO, MGX, ESLA, and MREO

Should you buy CytoMed Therapeutics stock or one of its competitors? MarketBeat compares CytoMed Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CytoMed Therapeutics include Dogwood Therapeutics (DWTX), Xilio Therapeutics (XLO), Metagenomi (MGX), Estrella Immunopharma (ESLA), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry.

How does CytoMed Therapeutics compare to Dogwood Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Dogwood Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 640.74%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Dogwood Therapeutics is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CytoMed Therapeutics' return on equity of 0.00% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
CytoMed Therapeutics	N/A	N/A	N/A

Dogwood Therapeutics has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market.

9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 0.3% of Dogwood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CytoMed Therapeutics has higher revenue and earnings than Dogwood Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
CytoMed Therapeutics	$250K	55.79	-$3.10M	N/A	N/A

In the previous week, Dogwood Therapeutics and Dogwood Therapeutics both had 3 articles in the media. CytoMed Therapeutics' average media sentiment score of 1.32 beat Dogwood Therapeutics' score of 0.96 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytoMed Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Dogwood Therapeutics beats CytoMed Therapeutics on 6 of the 11 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Xilio Therapeutics?

CytoMed Therapeutics (NASDAQ:GDTC) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

CytoMed Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. CytoMed Therapeutics' return on equity of 0.00% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytoMed Therapeutics	N/A	N/A	N/A
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

Xilio Therapeutics has a consensus price target of $28.00, suggesting a potential upside of 233.73%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Xilio Therapeutics is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, CytoMed Therapeutics had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for CytoMed Therapeutics and 2 mentions for Xilio Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.32 beat Xilio Therapeutics' score of 1.31 indicating that CytoMed Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytoMed Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xilio Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CytoMed Therapeutics has higher earnings, but lower revenue than Xilio Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytoMed Therapeutics	$250K	55.79	-$3.10M	N/A	N/A
Xilio Therapeutics	$53.48M	1.03	-$35.04M	-$3.55	N/A

0.0% of CytoMed Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CytoMed Therapeutics has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market.

Summary

CytoMed Therapeutics beats Xilio Therapeutics on 8 of the 14 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

CytoMed Therapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. CytoMed Therapeutics' return on equity of 0.00% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
CytoMed Therapeutics	N/A	N/A	N/A

Metagenomi has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market.

0.0% of CytoMed Therapeutics shares are held by institutional investors. 12.5% of Metagenomi shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CytoMed Therapeutics has lower revenue, but higher earnings than Metagenomi.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.83	-$87.87M	-$2.30	N/A
CytoMed Therapeutics	$250K	55.79	-$3.10M	N/A	N/A

In the previous week, Metagenomi had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 4 mentions for Metagenomi and 3 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.32 beat Metagenomi's score of 0.29 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytoMed Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Metagenomi presently has a consensus target price of $9.00, suggesting a potential upside of 634.69%. Given Metagenomi's stronger consensus rating and higher probable upside, equities analysts clearly believe Metagenomi is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Metagenomi beats CytoMed Therapeutics on 8 of the 15 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Estrella Immunopharma?

Estrella Immunopharma (NASDAQ:ESLA) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Estrella Immunopharma has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market.

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CytoMed Therapeutics has higher revenue and earnings than Estrella Immunopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
CytoMed Therapeutics	$250K	55.79	-$3.10M	N/A	N/A

In the previous week, CytoMed Therapeutics had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 3 mentions for CytoMed Therapeutics and 2 mentions for Estrella Immunopharma. CytoMed Therapeutics' average media sentiment score of 1.32 beat Estrella Immunopharma's score of 0.94 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytoMed Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
CytoMed Therapeutics	N/A	N/A	N/A

Estrella Immunopharma currently has a consensus price target of $8.00, indicating a potential upside of 644.19%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Estrella Immunopharma is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Estrella Immunopharma beats CytoMed Therapeutics on 6 of the 11 factors compared between the two stocks.

How does CytoMed Therapeutics compare to Mereo BioPharma Group?

Mereo BioPharma Group (NASDAQ:MREO) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Mereo BioPharma Group presently has a consensus price target of $3.25, suggesting a potential upside of 938.34%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe Mereo BioPharma Group is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CytoMed Therapeutics' return on equity of 0.00% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-81.28%	-70.45%
CytoMed Therapeutics	N/A	N/A	N/A

CytoMed Therapeutics has lower revenue, but higher earnings than Mereo BioPharma Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	99.92	-$41.88M	-$0.05	N/A
CytoMed Therapeutics	$250K	55.79	-$3.10M	N/A	N/A

In the previous week, Mereo BioPharma Group and Mereo BioPharma Group both had 3 articles in the media. CytoMed Therapeutics' average media sentiment score of 1.32 beat Mereo BioPharma Group's score of 1.30 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mereo BioPharma Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytoMed Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mereo BioPharma Group has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market.

Summary

Mereo BioPharma Group beats CytoMed Therapeutics on 8 of the 12 factors compared between the two stocks.

Get CytoMed Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GDTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GDTC vs. The Competition

Export

Metric	CytoMed Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.95M	$3.39B	$6.49B	$12.31B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	N/A	20.05	24.05	24.76
Price / Sales	55.79	325.48	542.61	168.32
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	2.62	8.16	10.69	6.90
Net Income	-$3.10M	$23.89M	$3.57B	$337.45M
7 Day Performance	2.52%	3.66%	1.56%	2.84%
1 Month Performance	1.64%	1.69%	2.49%	4.78%
1 Year Performance	-44.44%	46.95%	26.51%	33.08%

CytoMed Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GDTC CytoMed Therapeutics	1.2266 of 5 stars	$1.18 +3.4%	N/A	-46.3%	$13.95M	$250K	N/A	N/A	Positive News Insider Trade Gap Down
DWTX Dogwood Therapeutics	3.2043 of 5 stars	$1.55 -8.0%	$12.00 +676.7%	-66.9%	$51.96M	N/A	N/A	5	Short Interest Decrease Gap Up
XLO Xilio Therapeutics	2.5107 of 5 stars	$7.83 -5.7%	$28.00 +257.4%	-10.4%	$51.55M	$43.77M	N/A	70	Positive News Gap Down
MGX Metagenomi	3.1117 of 5 stars	$1.30 -2.6%	$9.00 +595.0%	-16.1%	$48.75M	$22.33M	N/A	236	News Coverage Analyst Upgrade Gap Down
ESLA Estrella Immunopharma	2.8161 of 5 stars	$1.13 -1.7%	$8.00 +608.0%	+10.4%	$48.63M	N/A	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GDTC) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CytoMed Therapeutics (GDTC) Competitors

GDTC vs. DWTX, XLO, MGX, ESLA, and MREO

How does CytoMed Therapeutics compare to Dogwood Therapeutics?

Summary

How does CytoMed Therapeutics compare to Xilio Therapeutics?

Summary

How does CytoMed Therapeutics compare to Metagenomi?

Summary

How does CytoMed Therapeutics compare to Estrella Immunopharma?

Summary

How does CytoMed Therapeutics compare to Mereo BioPharma Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GDTC vs. The Competition

CytoMed Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CytoMed Therapeutics (GDTC) Competitors

GDTC vs. DWTX, XLO, MGX, ESLA, and MREO

How does CytoMed Therapeutics compare to Dogwood Therapeutics?

Do analysts prefer DWTX or GDTC?

Is DWTX or GDTC more profitable?

Which has more risk and volatility, DWTX or GDTC?

Do institutionals & insiders have more ownership in DWTX or GDTC?

Which has higher earnings & valuation, DWTX or GDTC?

Does the media prefer DWTX or GDTC?

Summary

How does CytoMed Therapeutics compare to Xilio Therapeutics?

Is GDTC or XLO more profitable?

Do analysts recommend GDTC or XLO?

Does the media prefer GDTC or XLO?

Which has better valuation & earnings, GDTC or XLO?

Do insiders & institutionals have more ownership in GDTC or XLO?

Which has more volatility & risk, GDTC or XLO?

Summary

How does CytoMed Therapeutics compare to Metagenomi?

Is MGX or GDTC more profitable?

Which has more volatility & risk, MGX or GDTC?

Do insiders & institutionals have more ownership in MGX or GDTC?

Which has preferable valuation & earnings, MGX or GDTC?

Does the media refer more to MGX or GDTC?

Do analysts recommend MGX or GDTC?

Summary

How does CytoMed Therapeutics compare to Estrella Immunopharma?

Which has more volatility and risk, ESLA or GDTC?

Do institutionals and insiders believe in ESLA or GDTC?

Which has preferable valuation & earnings, ESLA or GDTC?

Does the media refer more to ESLA or GDTC?

Is ESLA or GDTC more profitable?

Do analysts rate ESLA or GDTC?

Summary

How does CytoMed Therapeutics compare to Mereo BioPharma Group?

Do institutionals and insiders hold more shares of MREO or GDTC?

Do analysts prefer MREO or GDTC?

Is MREO or GDTC more profitable?

Which has preferable valuation & earnings, MREO or GDTC?

Does the media favor MREO or GDTC?

Which has more volatility & risk, MREO or GDTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GDTC vs. The Competition

CytoMed Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools